ESMO Congress 2021
![Luís Castelo-Branco_ESMO 2021](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/luis-castelo-branco_esmo-2021/9283728-1-eng-GB/luis-castelo-branco_esmo-2021_i770.png)
Cancer is an independent risk factor for COVID-19 mortality in hospitalised patients
Findings from international registries improve knowledge on how to manage cancer care in the pandemic era
![Presidential 3_COVID](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/presidential-3_covid/9279636-1-eng-GB/presidential-3_covid_i770.jpg)
Efficacy of COVID-19 vaccine in cancer patients is comparable to levels reported in the general population
Initial delays to antibody production are followed by similar levels of vaccine efficacy after a second vaccine dose
![Resilience Task force survey_ESMO 2021](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/resilience-task-force-survey_esmo-2021/9282378-1-eng-GB/resilience-task-force-survey_esmo-2021_i770.png)
Some medical oncologists contemplate leaving the profession due to COVID-19
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
![Presidential 3_NETs](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/presidential-3_nets/9279552-1-eng-GB/presidential-3_nets_i770.jpg)
Rare NETs: sunitinib shows efficacy in pheochromocytoma and paraganglioma
Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors
![Speaker on stage with public 3](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/speaker-on-stage-with-public-3/9258303-1-eng-GB/speaker-on-stage-with-public-3_i770.jpg)
Can immunotherapy improve the treatment of advanced neuroendocrine neoplasms?
Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising
![Delegates walking 1](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/delegates-walking-1/9143826-1-eng-GB/delegates-walking-1_i770.png)
New cases of cancer are expected to reach 3.4 million in 2040 in Europe
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time
![Novel concepts on the horizon for the diagnosis and treatment of mesothelioma](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/editorial/novel-concepts-on-the-horizon-for-the-diagnosis-and-treatment-of-mesothelioma/9258243-1-eng-GB/novel-concepts-on-the-horizon-for-the-diagnosis-and-treatment-of-mesothelioma_i770.jpg)
Novel concepts on the horizon for the diagnosis and treatment of mesothelioma
Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.
![Public 5](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-5/9258147-1-eng-GB/public-5_i770.jpg)
Molecular profiling holds promise to speed up drug development in rare tumours
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
![Oosting_COVID vaccination](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/oosting_covid-vaccination/9275496-1-eng-GB/oosting_covid-vaccination_i770.jpg)
Adequate antibody response to SARS-CoV-2 vaccine in patients on chemotherapy or immunotherapy
Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns
![NeoTRIP_ESMO 2021](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/neotrip_esmo-2021/9275067-1-eng-GB/neotrip_esmo-2021_i770.png)
Immuno-oncology score predicts response to atezolizumab in TNBC
In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit